Beneficiaries

The Side-Out Foundation is closely involved with the allocation of funds and dedicates the majority of donations to translational research for breast cancer, a revolutionary science that aims to achieve bedside treatment as quickly as possible.  In addition to research, the foundation also allocates funds to organizations that provide emotional, educational and financial support for cancer patients and their families.

Teams may request that Side-Out donate up to 25 percent of funds that they raised to their local community.  In order to produce the greatest impact, Side-Out recommends donating that percentage to organizations offering patient and family support because it will have the most visible effects within the community. Side-Out will oversee the donation of these funds to ensure they are utilized properly. For local grant requests of 25 percent, click here.

As with any non-profit organization, a percentage of funds covers administrative costs of the organization to include travel, shipping, employee salaries and similar expenses.  For more detailed information, please refer to the rest of the financial information section where you will find specifics on the Side-Out donor pledge, financial disclosure and tax returns.

The Side-Out Protocol, a pilot study funded entirely by Side-Out supporters, is a clinical trial for patients with metastatic breast cancer that uses targeted therapy to develop the best treatment plan for each individual.  In September, 2011, Side-Out extended its involvement in clinical trials by donating funds to The Foundation for the National Institutes of Health (FNIH) I-SPY 2 breast cancer clinical trial.

 

We have allocated funding to the organizations listed below:

 

 

When choosing a non-profit organization to support, you will note that The Side-Out Foundation is much smaller than most. The smaller size allows it to ensure personal involvement through the entire research and patient support funding process. For more detailed information about Side-Out’s fiscal responsibility and its commitment to research, please contact Bryant Dunetz.


Advertisement